MELTF

Across TCGA pan-cancer cohorts, MELTF mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MELTF data layer compared with 21 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MELTF mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MELTF expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, UCEC, and HNSC are the cancer types where MELTF mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.683	0.886	<.001	88	view →
UCEC	DFS	Median	III,IV	0.424	1.000	.003	36	view →
HNSC	DFS	Quartile	All	0.511	0.835	.002	32	view →
LUAD	DFS	Median	III,IV	0.685	0.386	.009	16	view →
LSCC	OS	Median	II,III,IV	0.791	0.913	.008	15	view →
CCRCC	DFS	Median	All	0.471	1.000	.015	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MELTF–PDAC (DFS)

Open the PDAC breakdown →